浙江奥翔药业股份有限公司关于以集中竞价交易方式回购公司股份的进展公告

Group 1 - The company has approved a share repurchase plan using its own and/or raised funds, with a total repurchase amount between RMB 50 million and RMB 100 million, and a maximum repurchase price of RMB 14 per share, within a 12-month period [2] - Following the implementation of the 2024 annual equity distribution, the maximum repurchase price has been adjusted to RMB 13.90 per share starting from July 17, 2025 [3] - As of July 31, 2025, the company has repurchased a total of 1,999,400 shares, accounting for 0.24% of the total share capital, with a total payment of RMB 15,535,845.00, excluding transaction fees [4] Group 2 - The company's stock experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from July 29 to July 31, 2025 [10][11] - The company confirmed that there are no undisclosed significant matters affecting the stock price, and the production and operation are normal [12][13] - There were no media reports or market rumors identified that could significantly impact the stock price during the abnormal trading period [14]